Results 71 to 80 of about 47,298 (270)

GENERAL ETIOLOGY OF NERVOUS ACTIVITY DISTURBANCES. NEUROGENIC PATHOLOGICAL SYNDROMES

Вопросы современной педиатрии, 2013
The most clinically significant causes and the main links of mechanisms of development of neurogenic pathological syndromes are discussed in this lecture.
P. F. Litvitskii
doaj   +1 more source

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature

Muscle &Nerve, EarlyView.
ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza, Mattia Schiavolin, Francesca Beretta, Sara Cornacchini, Antonio Lotti, Gregorio Spagni, Valentina Damato   +6 more
wiley   +1 more source

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab

, 2016
Introduction: Myasthenia gravis (MG) is an antibody mediated autoimmune neuromuscular disorder characterized by fatigable muscle weakness. A proportion of myasthenia gravis patients are classified as refractory due to non responsiveness to conventional ...
Gummadi, S, Burra, HK, Sodalagunta, MB, Settikere Nataraju, Aravinda, Gummadi, Siddharth, Sudulagunta, SR, Burra, Hemanth Kumar, Sepehrar, M, Sathyanarayana, Deepak, Sudulagunta, Sreenivasa Rao, Bangalore Raja, Shiva Kumar, Sepehrar, Mona, Sodalagunta, Mahesh Babu, Settikere Nataraju, A, Sathyanarayana, D, Bangalore Raja, SK   +15 more
core   +1 more source

Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims The burden of myasthenia gravis (MG) is often underestimated, and studies usually focus on the symptom burden. However, treatment‐related adverse events also contribute to patients' burdens and affect their treatment decisions.
Meg Mendoza, Elena Wolff, Michael Chou, Vera Bril, Hans Katzberg, Ahmed Bayoumi, Carolina Barnett‐Tapia   +6 more
wiley   +1 more source

Cytokine Profiles in Myasthenia Gravis Subgroups and the Lack of Any Effect of Immunosuppression

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Myasthenia gravis (MG) is a clinically and immunologically heterogeneous autoimmune disease and there is little known about the differential effects of cytokines in disease subgroups. This study aimed to compare serum cytokine profiles across distinct MG subgroups, including early‐onset MG (EOMG), late‐onset MG (LOMG), muscle‐
Merve Cebi, Hacer Durmus, Arman Çakar, Mehmet Güven Günver, Yesim Parman, Feza Deymeer, Güher Saruhan‐Direskeneli   +6 more
wiley   +1 more source

Identification of metabolic biomarkers and therapeutic targets in the thymoma-associated myasthenia gravis treated with methylprednisolone

Discover Oncology
Objective This study aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis, thereby improving guidance for clinical ...
Shanshan Gu, Xu Wang, Hongxia Yang, Yaxuan Wang, Congya Yan, Xiaoting Lin, Peng Liu, Lu Liu, Li Meng, Guoyan Qi   +9 more
doaj   +1 more source

IgG Subclass (IgG1‐4) and IgA Autoantibody Profiles Against Muscle‐Specific Kinase in a Greek Cohort

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Muscle‐specific kinase myasthenia gravis (MuSK‐MG) is an autoimmune neuromuscular disorder predominantly mediated by IgG4 autoantibodies disrupting MuSK signaling. The contribution of other isotypes remains incompletely defined. We characterized the serological profile of a Greek cohort of MuSK‐MG patients.
Sofia‐Natsοuko Gkotzamani, Maria Pechlivanidou, Francisca Faber, Cansu Elmas, Vasiliki Zouvelou, Elisabeth Chroni, Dimitrios Tzanetakos, Maria Kourouvani, Marlene Wolfsgruber, Ioannis Zaganas, Dimitra Kolovou, Michael Rentzos, Ariadne Daponte, Maria Chondrogiorgi, Spyridon Konitsiotis, Georgios Nicolaou, Stavroula Salakou, Sotirios Giannopoulos, Konstandinos Lazaridis, Georgios Tsivgoulis, Socrates Tzartos, Inga Koneczny, John S. Tzartos   +22 more
wiley   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology
Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG)
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
doaj   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Thymoma with Myasthenia Gravis in Adolescent

, 2011
Thymomas are exceedingly rare in the first 20 years of life, Thymic lesions comprise approximately 2–3% of all pediatric mediastinal tumors and include thymic cysts, hyperplasia, carcinoma, and thymomas.
Shetty, Prasad K, Prasanna K Shetty,, Balaiah, K, Balaiah K,, Nayak, Ganesh, Shetty, Prasanna K, Ganesh Nayak,, Prasad K Shetty,   +7 more
core